The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

Merck MRK reported first-quarter 2025 adjusted earnings per share (EPS) of $2.22, which beat the Zacks Consensus Estimate of ...

Merck (NYSE:MRK) experienced a 2.98% share price increase over the past week, during which several key developments occurred. The company reaffirmed its 2025 financial guidance, despite a slight ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Pharmaceuticals giant Merck & Company (MRK) has cut its full-year profit forecasts fearing a $200 million hit from President ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

Merck MRK will report its first-quarter 2024 earnings on April 24, before market open. The Zacks Consensus Estimate for first ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...